Candriam Luxembourg S.C.A. boosted its position in shares of Radius Health, Inc. (NASDAQ:RDUS) by 94.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 115,000 shares of the biopharmaceutical company’s stock after buying an additional 56,000 shares during the period. Candriam Luxembourg S.C.A. owned about 0.27% of Radius Health worth $5,202,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Sei Investments Co. increased its stake in Radius Health by 27.7% in the second quarter. Sei Investments Co. now owns 3,180 shares of the biopharmaceutical company’s stock valued at $144,000 after buying an additional 690 shares during the period. Russell Investments Group Ltd. increased its stake in Radius Health by 144.2% in the second quarter. Russell Investments Group Ltd. now owns 12,562 shares of the biopharmaceutical company’s stock valued at $568,000 after buying an additional 7,417 shares during the period. Creative Planning increased its stake in Radius Health by 77.8% in the second quarter. Creative Planning now owns 29,665 shares of the biopharmaceutical company’s stock valued at $1,342,000 after buying an additional 12,980 shares during the period. Bank of Nova Scotia bought a new stake in Radius Health during the first quarter valued at about $1,933,000. Finally, Point72 Asset Management L.P. bought a new stake in Radius Health during the first quarter valued at about $1,256,000. Hedge funds and other institutional investors own 97.66% of the company’s stock.
Radius Health, Inc. (NASDAQ:RDUS) traded down 2.77% during midday trading on Thursday, reaching $35.42. The company had a trading volume of 793,696 shares. Radius Health, Inc. has a one year low of $31.58 and a one year high of $59.22. The company’s market capitalization is $1.54 billion. The stock’s 50 day moving average is $42.24 and its 200 day moving average is $40.17.
Radius Health (NASDAQ:RDUS) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.35) by $0.23. The company had revenue of $0.98 million for the quarter, compared to the consensus estimate of $1.96 million. During the same quarter last year, the company posted ($1.01) earnings per share. Equities research analysts forecast that Radius Health, Inc. will post ($5.51) earnings per share for the current fiscal year.
Several analysts have recently issued reports on the company. BidaskClub downgraded Radius Health from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Jefferies Group LLC reissued a “hold” rating and set a $38.00 price objective (up previously from $34.00) on shares of Radius Health in a research report on Wednesday, August 9th. Zacks Investment Research raised Radius Health from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. Canaccord Genuity set a $85.00 price target on Radius Health and gave the company a “buy” rating in a report on Monday, July 31st. Finally, Cantor Fitzgerald set a $58.00 price target on Radius Health and gave the company a “buy” rating in a report on Sunday, July 23rd. Two analysts have rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $53.60.
In other Radius Health news, major shareholder Growth N. V. Biotech acquired 150,000 shares of Radius Health stock in a transaction that occurred on Thursday, August 10th. The shares were bought at an average price of $34.97 per share, with a total value of $5,245,500.00. Following the completion of the purchase, the insider now directly owns 5,113,799 shares in the company, valued at approximately $178,829,551.03. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Growth N. V. Biotech acquired 40,000 shares of Radius Health stock in a transaction that occurred on Tuesday, May 30th. The stock was acquired at an average cost of $34.21 per share, for a total transaction of $1,368,400.00. Following the purchase, the insider now owns 5,038,799 shares of the company’s stock, valued at $172,377,313.79. The disclosure for this purchase can be found here. In the last three months, insiders purchased 230,000 shares of company stock worth $8,063,900. 15.00% of the stock is currently owned by insiders.
About Radius Health
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
